 |
|
|
| |
A budget optimization analysis for the treatment and potential
elimination of hepatitis C virus infection in the United States
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Olivier Ethgen1,2, Yuri Sanchez Gonzalez3, Jordan J. Feld4
1SERFAN innovation, Namur, Belgium; 2University of Liege, Liege, Belgium; 3AbbVie Inc., North Chicago, IL, USA; 4Toronto Centre for Liver Disease, Toronto, ON, Canada
|
| |
|
|
|
|
|
